BOLETÍN HTA

71 / 88

HIPERTENSIÓN / 2015 / VOL. 20
69
Bibliografía
1. MINSAL 2009;Pages. Accessed at Ministerio de Salud at on 29-12-2014 2014.
2. McCormack T, Cappucio F. 10 Steps Before You Refer for: Hypertension. 2008.
3. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Jr., Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9(4 Pt 1):342-60.
4.
5. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation
and validation of QRISK2. BMJ. 2008;336(7659):1475-82.
6. McCormack T, Krause T, O'Flynn N. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract. 2012;62(596):163-4.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement
From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-19.
8. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5
Pt 1):619-26.
9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens
based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31.
10. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment
on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049-51.
11. Bansal N, Tendler BE, White WB, Mansoor GA. Blood pressure control in the hypertension clinic. Am J Hypertens. 2003;16(10):878-80.
12. Dickerson LM, Gibson MV. Management of hypertension in older persons. Am Fam Physician. 2005;71(3):469-76.
13. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015;36(40):2686-95.
14. Varleta P, Akel C, Acevedo M, Salinas C, Pino J, Opazo V, et al. [Assessment of adherence to antihypertensive therapy]. Rev Med Chil. 2015;143(5):569-76.
15. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
16. Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring). 2014;22 Suppl 2:S41-410.
17. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement
from the American Heart Association Nutrition Committee. Circulation. 2006;114(1):82-96.
18. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the
American Heart Association. Hypertension. 2006;47(2):296-308.
19. Burnier M, Wuerzner G, Bochud M. Salt, blood pressure and cardiovascular risk: what is the most adequate preventive strategy? A Swiss perspective.
Front Physiol. 2015;6:227.
20. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension. 1991;18(1):67-71.
21. Bray GA, Vollmer WM, Sacks FM, Obarzanek E, Svetkey LP, Appel LJ. A further subgroup analysis of the effects of the DASH diet and three dietary sodium
levels on blood pressure: results of the DASH-Sodium Trial. Am J Cardiol. 2004;94(2):222-7.
22. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches
to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10.
23. Alcohol and hypertension--implications for management. A consensus statement by the World Hypertension League. J Hum Hypertens. 1991;5(3):227-32.
24. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled
trials. Hypertension. 2001;38(5):1112-7.
25. Cappuccio FP. Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease. BMJ. 2008;336(7655):1248-9.
26. Lip GY, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2004(3):CD003186.
27. Valdés S G, Roessler B E. Recomendaciones para el manejo de las crisis hipertensivas: Documento de Consenso de la Sociedad Chilena de Hipertensión
Arterial. Revista médica de Chile. 2002;130:322-31.
28. 2015;Pages. Accessed at NICE at
29. Vidt DG. Hypertensive Crises: Emergencies and Urgencies. The Journal of Clinical Hypertension. 2004;6(9):520-5.
En pacientes con sospecha de feocromocitoma basado en la presencia de hipotensión
postural, cefalea, palpitaciones, palidez y diaforesis, la derivación debe ser lo más precoz
posible a un centro terciario, sea endocrinólogo, nefrólogo o cardiólogo(28).
En cambio en pacientes con PA muy elevados, incluso mayores de 180/110 mm Hg, pero sin
evidencias de daño vascular de tipo maligno y sin estar cursando un accidente cerebrovascular,
crisis isquemia transitoria, angina inestable, insuficiencia cardíaca, infarto del miocardio o
edema pulmonar agudo, se puede iniciar en ese momento terapia combinada o incluso
triple terapia de antihipertensivos, controlando al paciente dentro de un periodo de entre 24
horas o una semana(29). En estos puede ser útil que sea controlado por enfermeras si la carga
asistencial es alta, y luego determinar si requiere o no ser referido a un centro especializado.